- Market Realist•18 minutes ago
Launched in the US in 1Q15, Novartis’s (NVS) Cosentyx managed to report revenues of around $1,128 million in 2016.
- Market Realist•14 hours ago
To boost its total net profit margins, Novartis (NVS) has been reducing expenses by capturing cross-divisional synergies.
- Market Realist•15 hours ago
While patent expiries had a negative impact on Novartis’s (NVS) revenues, the solid launch of Cosentyx partially offset the negative effect.
NVS : Summary for Novartis AG - Yahoo Finance
Novartis AG (NVS)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Bid||74.50 x 200|
|Ask||77.77 x 100|
|Day's Range||74.83 - 75.29|
|52 Week Range||66.93 - 83.58|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||26.73|
|Dividend & Yield||2.75 (3.66%)|
|1y Target Est||N/A|